Recruiting

Thrombectomy for Large Vessel Occlusion Stroke Beyond 24 Hours with Collateral Flow

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Endovascular Thrombectomy

Procedure
Who is being recruted

Ischemic Stroke+5

+ Brain Diseases

+ Cardiovascular Diseases

Over 18 Years
+23 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: June 2024
See protocol details

Summary

Principal SponsorTianjin Huanhu Hospital
Study ContactMing Wei, MD, PhDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 25, 2024

Actual date on which the first participant was enrolled.

This clinical trial is examining whether a procedure called endovascular treatment (EVT) is a better option for patients who have had a stroke due to a blockage in a large blood vessel. Typically, treatments are given within 24 hours of stroke symptoms, but this study focuses on those who present after this period. The trial aims to determine if EVT can help these patients become more independent 90 days after their stroke and to compare its safety with the current best medical management (BMM). This research could lead to improved treatment options for stroke patients who seek care later than usual. Participants in the study will either receive EVT or continue with BMM, depending on their suitability for the treatments. Before treatment, a special scan called CT angiography will be used to check blood flow in the brain and confirm the blockage. Over the course of 90 days, researchers will monitor participants to see how well they recover and to ensure the treatments are safe. This approach helps in understanding the effectiveness and safety of EVT when administered beyond the usual time frame.

Official TitleThrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography: A Multicentre, Open-label, Registry-linked, Randomised Controlled Trial
NCT06654375
Principal SponsorTianjin Huanhu Hospital
Study ContactMing Wei, MD, PhDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

350 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Ischemic StrokeBrain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersNervous System DiseasesVascular DiseasesStroke

Criteria

8 inclusion criteria required to participate
Confirmation of ICA or MCA-M1 occlusion, as detected by MRA or CTA, with carotid occlusions potentially occurring in either the cervical or intracranial regions, and the possibility of accompanying tandem MCA lesions.
Demonstration of moderate to good collateral flow, as evidenced by CTA imaging.
The patient must be aged 18 years or older.
The baseline NIHSSS score is equal to or greater than 2, and this score remains equal to or greater than 2 immediately prior to randomization.
Show More Criteria
15 exclusion criteria prevent from participating
The subject has a serious, advanced, or terminal illness (as determined by the investigator) or a life expectancy of less than six months.
The subject has a pre-existing medical, neurological, or psychiatric disease that would interfere with neurological or functional evaluations, or is already participating in another drug or device study.
The subject is pregnant.
The subject has contraindications for both MRI and CT contrast that prevent an MRI or CT contrast perfusion study. The hospital's local standard criteria should be applied to determine if contraindications exist.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Tianjin Huanhu Hospital

Tianjin, ChinaOpen Tianjin Huanhu Hospital in Google Maps
Recruiting
One Study Center